[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"angina-stable\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:angina-stable":127},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,48,76,113,155,185,224,254,274,300,330,357,380,409,425,447,474],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100622653","study-of-lesion-specific-invasive-haemodynamic-angina-thresholds-100622653",false,"NCT07386418","Study of Lesion-Specific Invasive Haemodynamic Angina Thresholds","ORBITA-SOLAR","Inclusion Criteria:\n\n1. Eligibility for PCI due to angina or angina-equivalent symptoms on exertion\n2. 2 severe epicardial stenoses in a major coronary artery, defined as:\n\n   1. ≥70% stenosis in a coronary artery with ≥2.5mm diameter, on invasive coronary angiography (ICA)\n   2. Severe stenosis in a vessel with ≥2.5mm diameter, on CTCA\n3. Evidence of ischaemia on an invasive or non-invasive test, including:\n\n   1. Physiological test during invasive coronary angiography (ICA)\n   2. Dobutamine stress echocardiography (DSE)\n   3. Stress perfusion cardiac magnetic resonance (CMR)\n   4. Myocardial perfusion scintigraphy (MPS)\n   5. Fractional flow reserve computed-tomography (FFR-CT)\n\nExclusion Criteria:\n\n1. Age \\\u003C18 years\n2. Acute coronary syndrome within 3 months\n3. Previous coronary artery bypass graft\n4. Significant left main stem disease\n5. Single lesion amenable to PCI\n6. Chronic total occlusion of the target artery\n7. Moderate to severe valve disease\n8. LVEF ≤40%, contraindication to PCI or drug-eluting stents\n9. PCI performed with drug-eluting balloons without stenting\n10. Contraindication to antiplatelet therapy\n11. Contraindication to adenosine\n12. Physical inability to exercise with an ergometer\n13. Femoral artery access\n14. Pregnancy\n15. Inability to consent","ALL","18 Years",{"count":19,"type":20},60,"ESTIMATED","INTERVENTIONAL",[23],"NA","ORBITA-SOLAR is an invasive physiological cardiac catheterisation study that aims to determine whether different coronary stenoses have different angina thresholds. The angina threshold is defined as the amount of coronary flow reduction required to reproduce symptoms. Sixty patients with symptoms of stable angina and 2 coronary artery stenoses amenable to percutaneous coronary intervention (PCI) will be recruited. This study will use intra-coronary balloon inflation during supine exercise on an ergometer to measure the fractional flow reserve (FFR) and non-hyperemic pressure ratio (NHPR) that relates to angina onset, in real time, at the location of each stenosis.",[26,27,28],"Angina (Stable)","Coronary Artery Disease(CAD)","Ischaemic Heart Disease (IHD)",[30,31,32,33,34],"Angina","Coronary physiology","Coronary haemodynamics","Placebo-control","Symptoms","RECRUITING","2026-06-23",{"date":38,"type":39},"2026-06-26","ACTUAL",{"date":41,"type":39},"2026-02-10",{"date":43,"type":20},"2028-12",{"name":45,"class":46},"Imperial College London","OTHER",7,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":57,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100643138","advanced-invasive-diagnosis-strategy-for-post-pci-patients-with-stable-coronary-syndromes-undergoing-coronary-angiography-100643138","NCT07638137","Advanced Invasive Diagnosis Strategy for Post-PCI Patients With Stable Coronary Syndromes Undergoing Coronary Angiography","Advanced Invasive Diagnosis Strategy for Post-PCI Patients With Stable Coronary Syndromes Undergoing Coronary Angiography: the AID Post-PCI Angina Study","Inclusion Criteria:\n\n* Patients with a history of previous percutaneous coronary intervention (PCI) with drug eluting stent (DES), bare metallic stent (BMS), or drug coated balloon (DCB) due to acute coronary syndrome or chronic coronary syndrome, who presented with angina or documented myocardial ischemia by non-invasive testing and are referred for invasive coronary angiography.\n\nExclusion Criteria:\n\n* Acute myocardial infarction (ST-segment elevation myocardial infarction \\[STEMI\\] and non-ST-segment elevation myocardial infarction \\[NSTEMI\\]).\n* Age \\\u003C 18 years old.\n* Pregnancy.\n* Severe left ventricle systolic dysfunction (left ventricular ejection fraction ≤30 %).\n* Congestive heart failure with reduced ejection fraction.\n* Concomitant severe valvular heart disease.\n* Severely decreased renal function (glomerular filtration rate \\\u003C 30 mL\u002Fmin\u002F1.73 m2).\n* Significant epicardial coronary artery disease unable to be treated by PCI.\n* Previous coronary artery bypass grafting (CABG).\n* Presence of any anatomic features precluding intracoronary instrumentation with pressure guidewires.\n* Contraindications to the administration of adenosine or acetylcholine.",{"count":56,"type":20},246,"12 Months","OBSERVATIONAL","AID Post-PCI Angina is as an observational, prospective, single-cohort, multicenter study designed to investigate the causes and origins of post-PCI angina by using the advance invasive diagnosis (AID) strategy combining with angiography derived physiology (ADP) in an all-comers population of patients with post-PCI angina referred for invasive coronary angiography. An all-comers population of patients with a history of previous percutaneous coronary intervention (PCI), who presented with angina or documented myocardial ischemia by non-invasive testing and are referred for invasive coronary angiography (ICA) will be enrolled. ICA will be performed with the application of the structure AID strategy to evaluate both obstructive and non-obstructive cause of myocardial ischemia. Then, angiography derived physiological assessment of epicardial coronary artery using functional coronary angiography in each vessel will be performed in both index procedure and the previous procedure in all patients. By combining information obtained from both procedures, the causes and origins of post-PCI angina will be made. Treatment will be decided by the operators according to the result. Patients will complete the Seattle Angina Questionnaire (SAQ) at baseline and at 1, 6, and 12 months after the procedure. The main hypothesis of this study states that, in patients with post-PCI angina referred to ICA, the application of the structured AID strategy combining with angiography derived physiology (ADP) will lead to a high diagnostic yield in identifying the origins of obstructive disease and causes of post-PCI angina.",[26,61,62,63],"Percutaneous Coronary Intervention (PCI)","INOCA (Ischemia With Non Obstructive Coronary Artery Disease)","Chronic Coronary Syndrome",[30,65,63],"Percutaneous Coronary Intervention","2026-06-04",{"date":68,"type":39},"2026-06-10",{"date":70,"type":39},"2025-03-12",{"date":72,"type":20},"2028-03-30",{"name":74,"class":46},"Fundacion Investigacion Interhospitalaria Cardiovascular",5,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":16,"minAge":84,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":87,"conditions":88,"keywords":94,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":112},"100631593","validation-of-remote-photoplethysmography-rppg-derived-cardiovascular-parameters-against-standard-clinical-measurements-and-risk-scores-in-a-community-100631593","NCT07502703","Validation of Remote Photoplethysmography (rPPG)-Derived Cardiovascular Parameters Against Standard Clinical Measurements and Risk Scores in a Community","Validation of Remote Photoplethysmography (rPPG)-Derived Cardiovascular Parameters Against Standard Clinical Measurements and Risk Scores in a Community-Based Population in Semanan, Jakarta","Inclusion Criteria:\n\n1. Adults aged ≥30 years\n2. Willing to participate and provide informed consent\n3. Able to undergo face scan, clinical examination, and laboratory testing\n\nExclusion Criteria:\n\n1. Facial abnormalities interfering with rPPG signal acquisition\n2. Inability to remain still during measurement\n3. Severe clinical instability\n4. Incomplete key variables",true,"30 Years",{"count":86,"type":20},300,"The goal of this observational study is to evaluate whether a contactless camera-based technology, called remote photoplethysmography (rPPG), can accurately measure cardiovascular parameters and estimate cardiovascular risk in adults aged 30 years and older living in a community setting in Semanan, Jakarta. This study aims to determine if rPPG can be used as a simple and accessible tool for early cardiovascular screening.\n\nThe main questions it aims to answer are:\n\n1. Do cardiovascular parameters measured using rPPG (such as blood pressure, heart rate, and cardiac workload) agree with standard clinical measurements?\n2. Do cardiovascular risk estimates generated by rPPG (such as ASCVD risk and Framingham heart age) correspond to risk calculations obtained using conventional clinical and laboratory methods?\n\nResearchers will compare results obtained from rPPG-based facial video scans with results from standard medical assessments, including blood pressure measurements, heart rate evaluation, and laboratory tests for cholesterol levels, to determine the level of agreement and accuracy.\n\nParticipants will:\n\n1. Undergo a short facial video scan (approximately 30-60 seconds) using an rPPG-based system\n2. Receive standard clinical assessments, including blood pressure and heart rate measurements\n3. Provide basic health information (such as age, sex, smoking status, and treatment history) Undergo simple laboratory testing for cholesterol levels\n\nThis study is expected to help determine whether rPPG can be used as a reliable, non-invasive, and scalable screening tool for cardiovascular risk in community and primary healthcare settings.",[89,26,90,91,92,93],"Dyslipidemia","Coronary Artery Disease (CAD)","Heart Disease","Hypertension","Diabetes (DM)",[95,96,97,98,99,100,101],"remote photoplethysmography","rPPG","cardiovascular risk","ASCVD","Framingham score","digital health","screening tool","NOT_YET_RECRUITING","2026-04-15",{"date":105,"type":39},"2026-04-20",{"date":107,"type":20},"2026-04-23",{"date":109,"type":20},"2026-12-30",{"name":111,"class":46},"Tarumanagara University",1,{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":21,"phases":123,"briefSummary":124,"conditions":125,"keywords":136,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":154},"100414271","icormica---stratified-medicine-in-angina-100414271","NCT04674449","iCorMicA - Stratified Medicine in Angina","International Study of Coronary Microvascular Angina (iCorMicA): a Randomised, Controlled, Multicentre Trial and Registry","iCorMicA","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. A clinical plan for invasive coronary angiography.\n3. Symptoms of angina (typical or atypical) according to the Rose- and\u002For Seattle Angina questionnaires.\n4. Able to comply with study procedures.\n5. Able to provide informed consent.\n\nExclusion Criteria:\n\n1. A non-coronary primary indication for invasive angiography (e.g. valve disease, heart failure).\n2. History of coronary artery bypass surgery.\n3. Presence of obstructive disease evident in a main coronary artery (diameter \\>2.5 mm), i.e. a coronary stenosis \\>50% and\u002For a fractional flow reserve (FFR) ≤0.80\\*.\n4. Logistical reason\\*. \\*These patients will enter a follow-up registry.",{"count":122,"type":20},1500,[23],"The iCorMicA study is a multicentre, prospective, randomised, double-blind, sham-controlled, parallel-group, end-point trial and registry. The investigators seek to determine whether stratified medical therapy guided by an adjunctive interventional diagnostic procedure (IDP) during the invasive management of patients with known or suspected angina but no obstructive coronary artery disease improves symptoms, wellbeing, cardiovascular risk and clinical outcomes.",[126,127,128,129,130,131,132,133,134,135],"Microvascular Angina","Angina, Stable","Ischemia With No Obstructive Coronary Arteries (INOCA)","Coronary Microvascular Dysfunction (CMD)","Ischaemic Heart Disease","Non-Obstructive Coronary Atherosclerosis","Coronary Artery Disease","Vasospastic Angina","Coronary; Ischemic","Angina Attacks",[137,138,139,140,141,142,143,144],"angina","microvascular angina","ischaemia with no obstructive coronary artery disease (INOCA)","stratified medicine","clinical trial","outcomes research","prognosis","health economics","2026-04-03",{"date":147,"type":39},"2026-04-09",{"date":149,"type":39},"2020-12-30",{"date":151,"type":20},"2030-12-31",{"name":153,"class":46},"NHS Greater Glasgow and Clyde",39,{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":21,"phases":165,"briefSummary":166,"conditions":167,"keywords":168,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":4},"100630308","coronary-sinus-reducer-therapy-for-persisting-angina-100630308","NCT07485985","Coronary Sinus Reducer Therapy for Persisting Angina","Impact of the Coronary Sinus Reducer on Invasive Hemodynamics and Angina in Patients With Advanced Coronary Artery Disease","REDUCE ANGINA","Inclusion Criteria:\n\n* Angina - Canadian Cardiovascular Society Class II-IV on at least two anti-anginals or maximally tolerated medical therapy if less than two.Hemodynamically significant epicardial coronary artery disease in the LAD, defined as an FFR≤0.80 and\u002For NHPR≤0.89.\n* No conventional revascularization options or considered unsuitable as determined by the local heart team.\n* Anatomically suitable for instrumentation of the left anterior descending coronary artery with a coronary pressure wire and infusion microcatheter.\n* Patient understands the nature of the procedure and provides written informed consent for the study prior to enrolment.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years.\n* Absence of symptoms reported on the ORBITA-app during the 2-week screening period.\n* Mean right atrial pressure ≥15 mmHg\n* Severe pulmonary hypertension.\n* Coronary sinus anatomy not suitable for CSR implantation.\n* Pregnancy or planned pregnancy within the next 12 months.\n* Recent acute coronary syndrome (within 3 months).\n* Recent revascularization with PCI (within 6 months).\n* Severe arrhythmias, including chronic atrial fibrillation with persistent rapid ventricular response (\\>100bpm despite medication).\n* Indication for cardiac resynchronization therapy.\n* Severe left ventricular impairment (left ventricular ejection fraction \\\u003C30%).\n* NYHA class IV or decompensated heart failure or hospitalization due to heart failure within 90 days before the index procedure.\n* Recent implantation of a permanent pacemaker or defibrillator lead in the right ventricle or atrium (within 90 days before the index procedure).\n* Presence of a pacemaker lead in the coronary sinus.\n* Severe valvular heart disease.\n* History of tricuspid valve replacement or repair.\n* Kidney failure (estimated glomerular filtration rate \\\u003C30ml\u002Fmin)\n* Contra-indication to short term dual antiplatelet therapy or lifelong aspirin treatment.\n* Currently enrolled in another investigational device or drug trial that has not completed the primary endpoint or that clinically interferes with the current study endpoints.\n* Unable or unwilling to use the ORBITA app\n* Known inability to tolerate contrast medium.\n* Life expectancy \\\u003C1 year.",{"count":164,"type":20},25,[23],"Refractory angina due to advanced obstructive coronary artery disease (CAD) remains a major clinical problem with limited evidence-based treatment options. The coronary sinus reducer (CSR) is an hourglass-shaped stainless-steel mesh device designed to create a controlled narrowing of the coronary sinus (CS). By increasing CS pressure, CSR implantation may improve myocardial perfusion and reduce anginal symptoms, although the physiological mechanisms underlying this effect remain incompletely understood.\n\nREDUCE-ANGINA is a prospective observational study investigating the hemodynamic effects of CSR implantation in 25 patients with refractory angina and advanced CAD. The study evaluates the interaction between coronary sinus hemodynamics and coronary arterial blood flow before and after CSR implantation. The main study endpoints include changes in coronary sinus pressure, coronary flow reserve, microvascular resistance reserve, and absolute microvascular resistance from baseline to 6 months, measured using continuous flow thermodilution during saline-induced coronary hyperemia.",[132,26],[169,170,132,171,172,173,174,175],"Coronary Sinus Reducer","Refractory Angina","Coronary Sinus Hemodynamics","Coronary Flow Reserve","Microvascular Resistance","Continuous Flow Thermodilution","Coronary Physiology","2026-03-17",{"date":178,"type":39},"2026-03-20",{"date":180,"type":20},"2026-04-01",{"date":182,"type":20},"2028-07-01",{"name":184,"class":46},"UMC Utrecht",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":16,"minAge":193,"maxAge":194,"enrollmentInfo":195,"targetDuration":4,"studyType":21,"phases":197,"briefSummary":198,"conditions":199,"keywords":204,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":223},"100576667","aerobic-exercise-induced-effect-on-endothelial-function-in-patients-with-ischaemic-heart-disease-100576667","NCT06788275","Aerobic Exercise-induced Effect on Endothelial Function in Patients With Ischaemic Heart Disease","Effect of Different Aerobic Exercise Methods in Cardiac Rehabilitation on Endothelial Function in Patients With Ischaemic Heart Disease and Study of the Associated Physiological Mechanisms (ENDO-R)","ENDO-R","Inclusion Criteria:\n\n* Men and women aged between 45 and 75 years.\n* Diagnosed with acute myocardial infarction, unstable or stable angina.\n* Treated with percutaneous coronary intervention, coronary artery bypass grafting, or conservative treatment.\n* Event or intervention within 3 to 12 months prior to participation in the study.\n* Fluency in speaking and reading Spanish.\n* Residing in Elche or surrounding areas and able to attend evaluations and the exercise programme (not planning to be absent for more than one week during the programme).\n* Functional Class I-II according to the New York Heart Association (NYHA) classification.\n* No physical limitations for exercise.\n* Stable optimal medical treatment.\n* Physically inactive, defined as 1) not meeting the World Health Organization recommendations for both aerobic and strength exercise, and 2) not participating in a structured exercise programme at least 3 days per week for more than 3 months. Both conditions must be met for inclusion. Note: Casual walking is not considered grounds for exclusion.\n\nExclusion Criteria:\n\n* Use of walking assistive devices.\n* Treatment with chemotherapy for any type of cancer in the past 2 years.\n* Hospitalisation in an intensive care unit in the past 6 months for reasons other than the ischaemic event.\n* Acute myocardial infarction group IV Killip-Kimball.\n* Obesity grade III (≥40.0 kg\u002Fm²).\n* Medical contraindication for inclusion in an exercise programme.\n* Diabetes with uncontrolled blood glucose levels.\n* Poorly controlled hypertension: resting blood pressure \\> 180\u002F110 mmHg.\n* Chest pain with exertion or ST-segment changes suggestive of residual ischemia during ergometry. Residual ischemia.\n* Severely reduced functional capacity on initial ergometry (\\<5 metabolic equivalent of task).\n* Left ventricular ejection fraction less than 50%.\n* Severe stenosis of the left main coronary artery (\\>50% significant disease).\n* Severe aortic stenosis, left ventricular outflow tract obstruction (e.g., obstructive hypertrophic cardiomyopathy) or aortic dissection.\n* Severe valvulopathy.\n* Acute pulmonary embolism or deep vein thrombosis.\n* Severe pulmonary hypertension.\n* Acute heart failure.\n* Acute endocarditis, myocarditis, or pericarditis.\n* Acute or chronic renal insufficiency (estimated glomerular filtration rate \\<30 ml\u002Fmin).\n* Pulmonary fibrosis or interstitial disease (severe respiratory insufficiency or confirmed chronic obstructive pulmonary disease).\n* Uncontrolled cardiac arrhythmias\u002Fhemodynamically unstable.\n* Permanent or persistent\u002Fparoxysmal atrial fibrillation with episodes in the past 6 months.\n* High-grade cardiac block.\n* Presence of implantable devices: cardiac resynchronization therapy pacemaker, implantable cardioverter defibrillators, or pacemaker.\n* Presence of ischaemic symptoms during the incremental exercise test performed before the intervention.\n* Severe autonomic or peripheral neuropathy.\n* Use of nitrates in pharmacological treatment.\n* Any planned surgical or medical intervention during the study period.\n* Plans to participate in or current participation in other studies that may interfere with this study.\n* Current pregnancy or intention to become pregnant during the study period.","45 Years","75 Years",{"count":196,"type":20},132,[23],"Endothelial dysfunction is one of the aetiological factors in ischaemic heart disease (IHD). Aerobic exercise is effective in improving endothelial function, as measured by flow-mediated dilation (FMD), in patients with IHD. Within the aerobic exercise methods, there is evidence showing that high-intensity interval training (HIIT) increases FMD to a greater extent than moderate-intensity training (MIT) in these patients. Notably, in a recent review, our research group found that only studies performing long bouts of HIIT (long HIIT: higher than 1 min) found a greater effect on FMD, while no differences were found in those studies using short bouts of HIIT (short HIIT: ≤ 1 min) and MIT. However, no experimental studies comparing the effect of long HIIT, short HIIT, and MIT on endothelial function, as well as other predictors of mortality, such as cardiorespiratory fitness, brain-derived neurotrophic factor (BDNF) levels or parasympathetic branch activity, have been performed. Therefore, the main objective of this project will be to compare the effect of the three aerobic exercise methods on endothelial function, as measured by FMD, in patients with IHD. Complementarily, the effect of aerobic exercise, depending on the exercise method, on different mortality predictors will be compared. For this purpose, a multicentre randomised study will be carried out (2 hospitals in Elche and one in Alicante). Assessors will be blinded to the patients allocation. Participants will be aware about their allocation in the experimental groups due to the nature of the study. A total of 132 men and women with IHD (66 per sex), diagnosed between three and 12 months before the start of the intervention, aged between 45 and 75 years, and without limitations for the practice of exercise training, will be recruited. All patients will train 3 days a week for 12 weeks. Participants will be assessed before the intervention (i.e., pre), at 6 weeks of training (i.e., mid) and after the intervention (i.e., post). Physiological and psychological variables will be registered in the assessment periods. Training intensity will be individually prescribed based on the cardiopulmonary exercise test (CPET). Intensity exercise will be adapted after the first part of the intervention. Analysis of covariance will be used to compare the values of the three groups after the intervention for the continuous variables, including the pre-intervention value as a covariate, while a logistic regression model will be used for the categorical variables.",[61,200,26,201,202,203],"Acute Myocardial Infarction","Unstable Angina Pectoris","Cardiorespiratory Fitness","Ischaemic Heart Diseases",[205,206,207,208,209,210,211,212],"Aerobic exercise","High-intensity interval training","Cardiac rehabilitation","Multicenter study","Coronary artery disease","Flow-mediated dilation","Nitroglycerin-mediated dilation","Mortality predictors","2026-02-25",{"date":215,"type":39},"2026-02-27",{"date":217,"type":39},"2024-11-01",{"date":219,"type":20},"2027-11",{"name":221,"class":222},"Instituto de Investigación Sanitaria y Biomédica de Alicante","NETWORK",2,{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":21,"phases":234,"briefSummary":235,"conditions":236,"keywords":240,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":253},"100621308","advanced-nanotherapies-dual-api-dcb-to-treat-de-novo-and-isr-lesions-in-patients-with-symptomatic-coronary-artery-disease-100621308","NCT07368933","Advanced NanoTherapies Dual-API DCB to Treat De-Novo and ISR Lesions in Patients With Symptomatic Coronary Artery Disease","ADVANCEd NanoTherapies SirPlux Duo™ Dual API-Coated PTCA Balloon Catheter to Treat Coronary In-stent Restenosis (ISR) and de Novo Lesions","ADVANCE-DUO","Inclusion Criteria:\n\n1. ≥18 years or minimum legal age as required by local regulations.\n2. Documented stable or unstable angina, positive functional test, or non -ST elevation myocardial infarction which, in the judgment of the operator, is attributable to disease in coronary vessel or in-stent restenosis, and the patient is deemed an appropriate candidate for PCI in accordance with the applicable guidelines on percutaneous coronary intervention.\n\n   Note: participants with NSTEMI must have enzymes that are trending down or are within normal limits prior to enrollment.\n3. Life expectancy \\>1 year in the Investigator's opinion.\n4. Participant is willing and able to cooperate with study procedures and follow-up evaluations.\n5. Treatment of only one target lesion required\n\n   1. Tandem lesions treated by a single DCB will be considered one target lesion.\n   2. Up to one de novo lesion in a separate vessel may be treated per standard of care at the procedure. Non-target lesions must be successfully treated under the same criteria of the target lesion, before treating the target lesion.\n6. Target lesion must be ≤36 mm in length.\n7. Target lesion must have a stenosis ≥ 50% and \\\u003C 100%.\n8. Target lesion must have a visually estimated reference vessel diameter of:\n\n   1. ISR lesions: 2.0 to 4.0 mm in diameter (inclusive)\n   2. de novo lesions: 2.0 to \\\u003C3.0 mm in diameter\n9. ISR lesions only: target lesion must be within a previous BMS or DES that does not extend \\>5.0 mm beyond the proximal or distal edge.\n\nExclusion Criteria:\n\n1. Participant is pregnant, or breastfeeding. Note: Participant of childbearing potential must have a negative pregnancy test within 7 days before procedure.\n2. Known hypersensitivity or contraindication to antiplatelet medications (e.g., aspirin; heparin; prasugrel); or a sensitivity to contrast media which cannot be adequately pre-medicated.\n3. History of an allergic reaction or significant sensitivity to paclitaxel, sirolimus, or any other analogue or derivative.\n4. Platelet count \\\u003C 100,000 cells\u002Fmm³ (i.e., 100 x 109 \u002FL) or \\> 700,000 cells\u002Fmm³ (i.e., 700 x 10 9 \u002FL), or a white blood cell (WBC) count \\\u003C 3,000 cells\u002Fmm³ within 7 days prior to procedure.\n5. Renal insufficiency (Serum creatinine level \\> 2.5 mg\u002Fdl (i.e., 221 μmol\u002FL) within 7 days prior to procedure) or failure (dialysis dependent).\n6. Evidence of an acute MI within 72 hours of the procedure Note: participants with NSTEMI are allowed, provided enzymes are trending down or are within normal limits prior to enrollment.\n7. Previous PCI of the target vessel within 6 months prior to procedure.\n8. History of a stroke or transient ischemic attack (TIA) within the prior 3 months to procedure (any prior stroke or TIA, if prasugrel is used).\n9. Planned PCI of any vessel within 30 days post-procedure and\u002For planned PCI of the target vessel within 12 months post-procedure.\n10. Active peptic ulcer or upper gastrointestinal (GI) bleeding within the prior 6 months to procedure.\n11. History of bleeding diathesis or coagulopathy or will refuse blood transfusions.\n12. Documented left ventricular ejection fraction (LVEF) \\\u003C30% at the most recent evaluation, within the prior 3 months to procedure.\n13. Planned surgery that would cause interruption in recommended DAPT duration per current guidelines.\n14. Currently participating in an investigational drug or another device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints; or requires additional coronary angiography, IVUS, or other coronary artery imaging procedures.\n15. The following criteria related to previous treatments applies based on the type of lesion treated. The participant is excluded in the following circumstances:\n\n    1. ISR lesions: If single-layer ISR, any previous treatment of the target vessel for restenosis. If double- layer ISR, any treatment of the double-layer ISR.\n    2. de novo lesions: any previous treatment of the target lesion.\n16. Planned PCI of three vessel disease during procedure.\n17. Planned treatment of more than one target vessel. Tandem lesions that can be treated by a single DCB are permissible.\n18. Target lesion requires treatment with atherectomy, laser, or thrombectomy procedure.\n19. Target vessel has other lesions with greater than 50% diameter stenosis based on visual estimate.\n20. Target vessel has evidence of thrombus.\n21. Target vessel is excessively tortuous, defined as more than one bend \\>90° to reach target lesion.\n22. Target lesion has any of following characteristics:\n\n    1. Lesion location is unprotected in left main coronary artery, internal mammary artery, aorto-ostial, bypass grafts, ostial lesions or within 5 mm of the origin of the left anterior descending or left circumflex.\n    2. Involves a side branch \\>2.0 mm in diameter.\n    3. Is severely calcified.\n23. The following criteria based on number and type of lesions:\n\n    1. ISR and de novo lesions: target lesion is in the same vessel with a de novo lesion requiring treatment.\n    2. ISR lesions: planned treatment of a ≥3 layer ISR lesion.",{"count":233,"type":20},30,[23],"The study objectives are:\n\n1. To evaluate the safety and performance of the SirPlux Duo PTCA to treat coronary ISR lesions 2.00-4.00 mm (inclusive) in diameter in patients with symptomatic coronary artery disease.\n2. To evaluate the safety and performance of the SirPlux Duo PTCA to treat coronary de novo lesions \\\u003C3.00 mm in diameter in patients with symptomatic coronary artery disease.",[26,237,238,239],"CAD - Coronary Artery Disease","Unstable Angina","NSTEMI - Non-ST Segment Elevation MI",[241,242,132],"DCB","Drug Coated Balloon","2026-01-23",{"date":245,"type":39},"2026-01-27",{"date":247,"type":39},"2025-12-15",{"date":249,"type":20},"2029-01",{"name":251,"class":252},"Advanced NanoTherapies","INDUSTRY",3,{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":260,"eligibilityCriteria":261,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":262,"targetDuration":4,"studyType":21,"phases":264,"briefSummary":265,"conditions":266,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":273,"locationsCount":112},"100545882","artificial-intelligence-in-anoca-100545882","NCT06387693","Artificial Intelligence in ANOCA","Artificial Intelligence-assisted Diagnostics In Angina With No Obstructive Coronary Artery Disease","(AI)NOCA","Inclusion Criteria:\n\n1. Clinical indication for comprehensive coronary function testing because of persisting chest discomfort at least 2 times per week despite current medical therapy.\n2. Absence of obstructive coronary artery disease with an indication for revascularization, documented by means of recent coronary computed tomography angiography (CCTA) or invasive coronary angiography (with invasive coronary pressure measurements if clinically indicated).\n3. Patient is willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n1. Absence of chest discomfort after initiation of medical therapy.\n2. Language barrier preventing sufficient understanding and communication in Dutch.",{"count":263,"type":20},250,[23],"Angina pectoris is diagnosed in \\>180.000 people in the Netherlands each year. Diagnosis in angina pectoris focuses on epicardial coronary stenosis, the identification of which may lead to guideline-directed medical therapy or revascularization. However, no such stenosis is identified in 40-70% of patients. This condition, angina with no obstructed coronary artery (ANOCA), is more prevalent in women and is related to poor quality of life, high medical expenses, and a higher incidence of adverse events.\n\nThe origin of ANOCA can be evaluated during invasive coronary angiography by coronary function testing (CFT) to identify coronary vasomotor disorders. This relates to vasospasm of the coronary artery and microcirculation, or to impaired microvascular vasodilation. For the diagnosis of vasospasm, CFT needs to result in electrocardiographic signs of myocardial ischemia as part of the diagnostic criteria. This is a critical point in the diagnosis of vasospasm, as these signs can be subtle and can vary, and are therefore prone to misinterpretation. Apart from this caveat, the diagnosis approach therefore currently requires an invasive procedure for the diagnosis. This limits the broad application and hampers early identification and treatment of ANOCA.\n\nDuring CFT, a coronary guide wire is routinely advanced in the coronary artery which also allows obtaining an intracoronary ECG by attaching a sterile alligator clamp to a standard electrocardiogram lead. This allows continuous recording of intracoronary ECG throughout CFT on the same monitor as the routine ECG. This technique can increase sensitivity for myocardial ischemia during CFT. Further, Holter ECG monitoring allows the identification of ischemic changes in the ECG in the outpatient setting. Evidence is lacking on the patterns of myocardial ischemia that occur during spontaneous angina pectoris symptoms in ANOCA patients, and on the sensitivity of Holter ECG for this purpose. Finally, the interpretation of ischemic patterns on ECG tracings can be cumbersome, especially when changes are subtle or change from beat to beat. The use of deep learning techniques allows to automate the interpretation of ECG traces and may improve the standardized diagnosis in ANOCA.",[127],"2026-01-08",{"date":269,"type":39},"2026-01-12",{"date":271,"type":39},"2024-12-03",{"date":43,"type":20},{"name":184,"class":46},{"id":275,"slug":276,"hasResults":11,"nctId":277,"briefTitle":278,"officialTitle":278,"acronym":4,"eligibilityCriteria":279,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":280,"targetDuration":4,"studyType":21,"phases":282,"briefSummary":283,"conditions":284,"keywords":289,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":291,"lastUpdatePostDateStruct":292,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":75},"100510949","mcnair-study-comparative-effectiveness-of-in-person-and-telehealth-cardiac-rehabilitation-100510949","NCT05933083","MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation","Inclusion Criteria:\n\n1. Age 18 or older\n2. Eligible for cardiac rehabilitation\n\n   1. Diagnosis within 1 year prior to consent\n\n      * Myocardial infarction\n      * Percutaneous coronary intervention\n      * Coronary artery bypass\n      * Heart valve repair or replacement\n      * Heart transplant\n   2. Chronic stable angina, or\n   3. Chronic systolic heart failure (ejection fraction ≤ 35%)\n   4. Referred to cardiac rehabilitation by a doctor or advanced practice provider for another indication that is covered by the participant's insurance, such as heart failure with preserved ejection fraction or aortic surgery.\n3. Willing to be randomized to in-person or telehealth cardiac rehabilitation\n4. Able to communicate in English or Spanish\n\nExclusion Criteria:\n\n1. Unstable arrhythmias which may make unmonitored exercise unsafe (e.g., history of ventricular tachycardia not on medical therapy and without an implantable cardioverter defibrillator)\n2. Unsafe for patient to participate in the opinion of the investigator\n3. Hospice\n4. Unable to consent for self",{"count":281,"type":20},516,[23],"Cardiac rehabilitation is a medically recommended program for patients with certain heart conditions. It includes exercise training, health education, and counseling. Unfortunately, many patients do not participate in cardiac rehabilitation. Some find it challenging to attend the in-person sessions. This study aims to compare two methods of delivering cardiac rehabilitation: in-person and through telehealth. The investigators want to know if the effects of these two programs are alike and if certain individuals benefit more from one program over the other.",[285,286,287,127,132,288],"Myocardial Infarction","Heart Failure, Systolic","Heart Valve Diseases","Heart Transplant",[290],"cardiac rehabilitation, telehealth","2025-09-09",{"date":293,"type":39},"2025-09-11",{"date":295,"type":39},"2023-10-27",{"date":297,"type":20},"2027-10-15",{"name":299,"class":46},"University of California, San Francisco",{"id":301,"slug":302,"hasResults":11,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":306,"eligibilityCriteria":307,"healthyVolunteers":83,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":308,"targetDuration":4,"studyType":21,"phases":310,"briefSummary":312,"conditions":313,"keywords":316,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":112},"100582509","phase-4-effect-of-beta-blockers-on-coronary-flow-and-resistance-in-patients-with-anoca-100582509","NCT06864234","Effect of Beta-blockers on Coronary Flow and Resistance in Patients With ANOCA","Effect of Beta-blockers on Coronary Flow and Resistance in Patients With ANOCA: a Randomised, Placebo-controlled, Mechanistic Study","BEACON","Inclusion Criteria:\n\n* Patients undergoing diagnostic coronary angiography for suspected angina pectoris who are found to have ANOCA i.e. an FFR \\>0.80 and no diameter stenosis \\>50%\n* Normal, TIMI 3 flow at angiography\n* Stable haemodynamics\n\nExclusion Criteria:\n\n* Clinical signs or symptoms of congestive heart failure\n* Severe valvular heart disease requiring either surgical or percutaneous intervention\n* History of coronary artery bypass grafting\n* Tortuous coronary anatomy in which wire manipulation could be complex\n* Heart rate \\\u003C60 beats per minute\n* Systolic blood pressure \\\u003C100 mmHg\n* Unable to give consent\n* LVEF\\\u003C40%",{"count":309,"type":20},46,[311],"PHASE4","The goal of this clinical trial is to learn whether beta-blockers can improve coronary blood flow and reduce resistance in patients with angina and no obstructive coronary arteries (ANOCA).\n\nThe main questions it aims to answer are:\n\n* Do beta-blockers improve coronary blood flow in patients with ANOCA?\n* Do beta-blockers reduce coronary microvascular resistance in these patients?\n\nResearchers will compare a beta-blocker to a placebo to see if the medication has measurable effects on coronary circulation.\n\nParticipants will:\n\n* Receive a beta-blocker or a placebo\n* Undergo specialized heart tests (such as coronary flow and resistance measurements) before and after treatment.",[314,26,315],"Coronary Arterial Disease (CAD)","Microvascular Circulation",[137,317,318,319,320],"coronary artery disease","absolute coronary flow","continuous intracoronary thermodilution","Beta-blockers","2025-07-08",{"date":323,"type":39},"2025-07-14",{"date":325,"type":39},"2025-07-03",{"date":327,"type":20},"2025-12-31",{"name":329,"class":46},"VZW Cardiovascular Research Center Aalst",{"id":331,"slug":332,"hasResults":11,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":336,"eligibilityCriteria":337,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":340,"conditions":341,"keywords":345,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":349,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":112},"100196816","biochemical-and-electrocardiographic-signatures-in-the-detection-of-exercise-induced-myocardial-ischemia-100196816","NCT01838148","Biochemical and Electrocardiographic Signatures in the Detection of Exercise-induced Myocardial Ischemia","BASEL VIII Trial - Biochemical and Electrocardiographic Signatures in the Detection of Exercise-induced Myocardial Ischemia","BASEL VIII","Inclusion Criteria:\n\n* Patients presenting with suspected exercise-induced myocardial ischemia referred for rest\u002Fergometry myocardial perfusion SPECT\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Pregnancy\n* Unable or unwilling to give informed consent\n* Symptoms at rest or minor exertion",{"count":339,"type":20},4000,"The primary aim is to perform the largest study worldwide to evaluate novel biochemical and electrocardiographic signatures alone as well as in combination with the standard 12-lead exercise ECG in the detection of exercise-induced myocardial ischemia (diagnostic endpoint). The secondary aim is to evaluate these innovative tools in the risk prediction for the occurrence of cardiovascular death and acute myocardial infarction during long-term follow-up.",[132,127,342,343,344],"Exercise Test","Biological Markers","SPECT",[317,346,347,348,344],"angina, stable","exercise test","biological Markers",{"date":350,"type":39},"2025-07-11",{"date":352,"type":4},"2004-05",{"date":354,"type":20},"2025-12",{"name":356,"class":46},"University Hospital, Basel, Switzerland",{"id":358,"slug":359,"hasResults":11,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":363,"eligibilityCriteria":364,"healthyVolunteers":11,"sex":16,"minAge":365,"maxAge":4,"enrollmentInfo":366,"targetDuration":4,"studyType":21,"phases":368,"briefSummary":369,"conditions":370,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":112},"100540024","effects-of-acupuncture-on-symptoms-of-stable-angina-100540024","NCT06311461","Effects of Acupuncture on Symptoms of Stable Angina","Effects of Acupuncture on Symptoms of Stable Angina: A Randomized Controlled Trial","EASE","Inclusion Criteria:\n\n* Diagnosis of stable angina or chest pain syndrome for at least 1 month (pain, pressure, or discomfort in the chest or other areas of the upper body)\n* Treated with medical therapy for at least 1 month\n* Experiencing symptoms at least once per week\n* Speak and read English\n* 21 years of age minimum\n\nExclusion Criteria:\n\n* Pregnancy as some acupuncture points included in the protocol are contraindicated in pregnancy\n* Physical or cognitive limitations that will prevent informed consent or completion of study tasks\n* Use of steroid or prescription analgesic medications\n* Concomitant biofeedback, professional massage and acupuncture.","21 Years",{"count":367,"type":20},112,[23],"The goal of this clinical trial is to determine if a standardized 12-point acupuncture protocol will reduce pain in participants with stable angina.\n\nThis study addresses the critical need to reduce persistent pain for angina. The investigators long-term goal is symptom management for diverse women and men with angina, targeting additional angina burden borne of social disadvantage\n\nParticipants will be randomized to a 10-acupuncture session protocol, two treatments per week for five weeks, or an attention control group. Participants will view designated, non-pain related Technology, Entertainment, Design Talks equal to the time spent receiving acupuncture (\\~7.5-10 hrs.).\n\nThe investigators will test the efficacy of acupuncture for stable angina\u002Fchest pain syndrome to reduce pain and symptoms, improve health-related quality of life, reduce healthcare utilization and and improve patient related health outcomes.",[127],"2025-03-30",{"date":373,"type":39},"2025-04-03",{"date":375,"type":39},"2024-04-01",{"date":377,"type":20},"2027-06-30",{"name":379,"class":46},"University of California, Los Angeles",{"id":381,"slug":382,"hasResults":11,"nctId":383,"briefTitle":384,"officialTitle":384,"acronym":385,"eligibilityCriteria":386,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":387,"targetDuration":389,"studyType":58,"phases":4,"briefSummary":390,"conditions":391,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":112},"100521900","complex-registry---a-prospective-cohort-study-to-describe-the-management-and-outcomes-of-patients-presenting-with-complex-and-calcified-coronary-artery-disease-100521900","NCT06075602","COMPLEX Registry - a Prospective COhort Study to Describe the Management and Outcomes of Patients Presenting with CompLEX and Calcified Coronary Artery Disease","COMPLEX","Inclusion Criteria:\n\n* Subject \\>18 years of age\n* Individuals presenting with chronic, complex and\u002For calcified CAD and requiring PCI or CABG\n* Complex coronary artery disease \u002F lesions must include at least one of the following attributes:\n* Long and\u002F or heavily calcified coronary lesions\n* In-stent restenosis\n* Chronic total occlusions (CTO)\n* Left main lesions\n* Bifurcation lesions\n* Bypass graft lesions\n* Small vessel disease \u002F coronary microvascular dysfunction (e.g. not amenable to PCI)\n* Subjects must be willing to sign a patient informed consent (PIC) or must have signed the General Consent (GK).\n\nExclusion Criteria:\n\nThe presence of any one of the following exclusion criteria will lead to exclusion of the patient.\n\n* Patient is \\\u003C18 years of age\n* Patient unwilling or unable to provide informed consent\n* Patients with no complex and calcified CAD",{"count":388,"type":20},5000,"10 Years","The purpose of the COMPLEX Registry is to prospectively and retrospectively collect baseline, clinical and procedural data of patients who have undergone PCI or CABG for complex and\u002F or calcified chronic CAD, irrespective of clinical presentation as well as to prospectively collect data about their clinical outcomes. The outcomes will be compared in different clinical subgroups (e.g. PCI vs. CABG). The impact of current PCI techniques\u002F devices, but also CABG strategies in different clinical settings and coronary artery lesions on cardiovascular outcomes will be assessed.",[392,132,393,394,395,396,397,127,398,399],"Coronary Disease","Coronary Restenosis","Coronary Arteriosclerosis","Coronary Artery Calcification","Stable Chronic Angina","Angina Pectoris","Angina, Unstable","Stent Thrombosis","2024-10-27",{"date":402,"type":39},"2024-10-29",{"date":404,"type":39},"2021-11-01",{"date":406,"type":20},"2031-12-31",{"name":408,"class":46},"Luzerner Kantonsspital",{"id":410,"slug":411,"hasResults":11,"nctId":412,"briefTitle":413,"officialTitle":413,"acronym":414,"eligibilityCriteria":415,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":416,"targetDuration":389,"studyType":58,"phases":4,"briefSummary":418,"conditions":419,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":420,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":424,"locationsCount":112},"100438392","siroop-registry---a-prospective-registry-study-to-evaluate-the-outcomes-of-coronary-artery-disease-patients-treated-with-sirolimus-or-paclitaxel-eluting-balloon-catheters-100438392","NCT04988685","SIROOP Registry - A Prospective Registry Study to Evaluate the Outcomes of Coronary Artery Disease Patients Treated With SIROlimus Or Paclitaxel Eluting Balloon Catheters","SIROOP","Inclusion Criteria:\n\n* Subject \\>18 years of age\n* Patients with significant acute or chronic coronary de-novo lesions or ISR lesions requiring treatment using PCI\n* Treatment with at least one DCB (device choice at the operator's discretion) In case of a patient with lesions treated at different procedural time, lesions will be separately collected and documented\n* Subjects must be willing to sign a patient informed consent (PIC) or must have signed the General Consent (GK).\n\nExclusion Criteria:\n\n* Patient is \\\u003C18 years of age\n* Patient unwilling or unable to provide informed consent\n* pregnancy and lactation\n* Indication for surgical revascularization",{"count":417,"type":20},2000,"The purpose of the SIROOP Registry is to retrospectively and prospectively collect baseline, clinical and procedural characteristics of patients who have undergone PCI and are treated with either currently available sirolimus or paclitaxel coated DCBs (see Table 1), irrespective of clinical presentation as well as to prospectively collect data about their clinical outcomes. Outcomes will be compared in different clinical subgroups. The impact of current DCBs in different clinical settings and coronary artery lesions on cardiovascular outcomes will be assessed.",[392,132,393,394,395,396,397,127,398,399],{"date":402,"type":39},{"date":422,"type":39},"2021-06-01",{"date":406,"type":20},{"name":408,"class":46},{"id":426,"slug":427,"hasResults":11,"nctId":428,"briefTitle":429,"officialTitle":429,"acronym":4,"eligibilityCriteria":430,"healthyVolunteers":83,"sex":16,"minAge":84,"maxAge":4,"enrollmentInfo":431,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":433,"conditions":434,"keywords":436,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":112},"100566484","performance-of-the-acoustic-based-cadscor-system-in-coronary-artery-disease-100566484","NCT06655779","Performance of the Acoustic Based CADScor System in Coronary Artery Disease","Inclusion:\n\n* Signed ICF\n* Male or female, aged 30 years or above\n* Symptoms suggestive of stable coronary artery disease\n* No history of coronary artery disease(prior myocardial infarction, percutaneous coronary intervention or coronary artery bypass graft).\n\nExclusion:\n\n* Asymptomatic for angina or chest pain\n* Implanted donor heart\n* Previous Coronary Artery Bypass Graft(CABG)\n* Previous Coronary Stenting or known CAD\n* Arrhythmia causing non-sinus rhythm\n* Fragile or compromised skin, or abnormal anatomy or significant operation scars in the fourth left int3er Costal 9IC4-L) recording area\n* Implanted mechanical heart or mechanical heart pump\n* Implanted pacemaker or Cardioverter Defibrillator(ICD), other implanted active electronics or act5ive electronic support equipment closer than 50 cm to the CADScore System.",{"count":432,"type":20},200,"The purpose of this study is to determine if the CAD Score, collected from the CADscore system, performs as well as the Coronary CTA in determining Coronary Artery Disease, in low to intermediate risk patients that are referred for coronary CTA.",[132,435],"Angina (stable)",[437],"CADScore","2024-10-22",{"date":440,"type":39},"2024-10-23",{"date":442,"type":20},"2024-11",{"date":444,"type":20},"2026-03",{"name":446,"class":46},"INTEGRIS Baptist Medical Center",{"id":448,"slug":449,"hasResults":11,"nctId":450,"briefTitle":451,"officialTitle":451,"acronym":452,"eligibilityCriteria":453,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":454,"enrollmentInfo":455,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":457,"conditions":458,"keywords":462,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":465,"lastUpdatePostDateStruct":466,"startDateStruct":468,"completionDateStruct":470,"leadSponsor":472,"locationsCount":112},"100551742","influence-of-air-quality-on-the-development-and-progression-of-premature-coronary-artery-disease-100551742","NCT06464042","Influence of Air Quality on the Development and Progression of Premature Coronary Artery Disease","AIRHEART","CASES:\n\nInclusion Criteria:\n\n* Women and men between 18 and 40 years old with a diagnosis of coronary artery disease coded in their medical records in Galicia\n\nExclusion Criteria:\n\n* Not having a postal code and primary care center assigned in their medical records in Galicia\n\nCONTROL\n\nInclusion Criteria:\n\n* Women and men between 18 and 40 years old with no diagnosis or history of CAD or other coronary disease coded in their medical records\n\nExclusion Criteria:\n\n* Present with non-ischemic coronary diseas.\n* Have a serious condition that affects or decreases life expectancy.\n* Do not have a postal code or primary care center assigned in their medical records in Galicia","40 Years",{"count":456,"type":20},4272,"The new global guidelines from the World Health Organization on air quality provide evidence of the damage that air pollution inflicts on human health at even lower concentrations than previously thought. Different studies have shown an increase in the incidence of coronary artery disease (CAD) in young people in recent decades. The main objective of this project is to study the impact of environmental pollutants on the premature manifestation of CAD from different epidemiological approaches and their impact on the evolution of these patients with a gender perspective. It is a retrospective analytical case-control study nested in a cohort of patients ≤40 years old with a clinical history of CAD including: ST-segment elevation myocardial infarction, non-ST-segment elevation acute coronary syndrome, unstable angina, stable angina or silent angina according to the international classification of diseases.",[459,127,460,461,285],"Coronary Artery Disease Premature","Acute Coronary Syndrome","MINOCA",[463,464,459],"Air pollution","young","2024-06-12",{"date":467,"type":39},"2024-06-18",{"date":469,"type":39},"2024-05-23",{"date":471,"type":20},"2025-07-01",{"name":473,"class":46},"pablo Juan-Salvadores",{"id":475,"slug":476,"hasResults":11,"nctId":477,"briefTitle":478,"officialTitle":479,"acronym":480,"eligibilityCriteria":481,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":482,"targetDuration":4,"studyType":21,"phases":484,"briefSummary":485,"conditions":486,"keywords":4,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":112},"100505173","clinical-outcomes-of-ct-ffr-versus-qfr-guided-strategy-for-decision-making-in-patients-with-stable-chest-pain-100505173","NCT05857904","Clinical Outcomes of CT-FFR Versus QFR-guided Strategy for Decision-Making in Patients With Stable Chest Pain","Clinical Outcomes of CoroNary CTA-Derived FFR Versus ICA-Derived QFR-guided Strategy for Decision-Making in Patients With Stable Chest Pain","CONFIDENT","Inclusion Criteria:\n\n* Age ≥18 years\n* with stable chest pain who underwent CCTA and have at least 1 lesion with a percent diameter stenosis (DS%) between 50% and 90% in a coronary artery with a ≥2.5 mm reference vessel diameter by visual assessment.These patients plan to undergo further non-invasive or invasive diagnosis and treatment.\n* Able to undergo invasive coronary angiography (ICA)\n* Capable of complying with the study procedures and fully understand the informed consent form approved by the ethics committee, and provide voluntary consent.\n\nExclusion Criteria:\n\nGeneral exclusion criteria:\n\n* Patients with acute coronary syndrome requiring urgent revascularization.\n* Patients with unstable angina, including those with first-onset chest pain within 48 hours, CCS III or higher first-onset angina, those whose angina has worsened to CCS III or IV within a short period of time, or those with rest angina lasting more than 20 minutes.\n* Patients with iodine contrast agent allergy.\n* Pregnant or lactating women.\n* Patients with severe congestive heart failure (NYHA III-IV or LVEF \\\u003C30%) or acute pulmonary edema.\n* Patients with severe renal insufficiency (creatinine \\>150μmol\u002FL or estimated - -glomerular filtration rate calculated by the Cockcroft-Gault formula \\\u003C45ml\u002Fkg\u002F1.73 m2).\n* Patients with other comorbidities and an expected survival time of less than 1 year.\n* Patients who, for any other reason, are considered by the investigators to be unsuitable for inclusion in the study or unable to complete the study and follow-up.\n\nCoronary CTA and coronary angiography exclusion criteria:\n\n* Patients with a body mass index \\>35 when undergoing coronary CT testing, resulting in poor CT image quality due to motion artifacts, severe calcification, or inadequate iodine contrast agent filling.\n* Patients with a history of coronary artery bypass grafting (CABG).\n* Target lesions related to acute myocardial infarction.\n* Target lesions involving left main stem disease.\n* Target lesions involving myocardial bridging.\n* Target lesions involving in-stent restenosis.\n* Low-quality angiography due to poor visualization of vascular boundaries or poor iodine contrast agent filling.\n* Excessive overlap of the stenotic segment or severe tortuosity of the target vessel, making QFR calculation impossible.\n\nRegen",{"count":483,"type":20},4648,[23],"This study is a multicenter, prospective, blinded (blinding of clinical evaluators), randomized controlled, event-driven non-inferiority clinical trial. Eligible subjects who meet the inclusion criteria will be registered in the central randomization system and randomized in a 1:1 ratio to either the experimental group (CT-FFR guided group) or the control group (QFR guided group).",[127,132],"2023-05-12",{"date":489,"type":39},"2023-05-15",{"date":491,"type":20},"2023-05",{"date":493,"type":20},"2028-05",{"name":495,"class":46},"Shanghai Zhongshan Hospital"]